Anti-CD45 Radioimmunotherapy using an Alpha-Emitting Radionuclide 211At Combined with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model ABSTRACT Despite aggressive chemotherapy combined with hematopoietic cell transplant (HCT), many patients with acute myeloid leukemia (AML) relapse. Radioimmunotherapy (RIT) using antibodies (Ab) labeled primarily with beta-emitting radionuclides has been explored to reduce relapse.
Revised: July 3, 2013 |
Published: May 15, 2013
Citation
Orozco J.J., T. Back, A.L. Kenoyer, E.R. Balkin, D.K. Hamlin, D. Wilbur, and D.R. Fisher, et al. 2013.Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Blood 121, no. 18:3759-3767.PNNL-22004.doi:10.1182/blood-2012-11-467035